首页> 外文期刊>Radiation oncology >A minimally invasive treatment option for large metastatic brain tumors: long-term results of two-session Gamma Knife stereotactic radiosurgery
【24h】

A minimally invasive treatment option for large metastatic brain tumors: long-term results of two-session Gamma Knife stereotactic radiosurgery

机译:大型转移性脑肿瘤的微创治疗方案:两期伽玛刀立体定向放射外科手术的长期结果

获取原文
获取外文期刊封面目录资料

摘要

Background Large brain metastases (BM) remain a significant cause of morbidity and death for cancer patients despite current advances in multimodality therapies. The goal of the present study was to evaluate the efficacy and limitations of 2-session Gamma Knife stereotactic radiosurgery (SRS) for patients with large BM. Methods This is a prospective, open-label and single arm study analyzing 58 consecutive patients who received 2-session SRS for large BM (≥?10?mL). The median age was 66?years, and the median Karnofsky performance status (KPS) score was 70. SRS was the initial treatment in 51 large tumors (84%) and was used as salvage after failed prior treatments for 10 tumors (16%). The fraction protocol was 20-30?Gy given in 2 fractions with 3–4 weeks between fractions. Overall survival (OS) and neurological death (ND), local tumor control and KPS were analyzed. Results The median follow-up time was 9.0?months. One- and 2-year OS rates were 47% and 20%, respectively. The median OS time was 11.8?months (95% CI: 5.5-15.6). The causes of death were intracranial local progression in 5 cases, meningeal carcinomatosis in 3 and progression of the primary lesion in 39. One- and 2-year ND-free survival rates were 91% and 84%, respectively. In 52 of 61 large BM (85%) with sufficient radiological follow-up data, 6- and 12-month local tumor control rates were 85% and 64%, respectively. The mean KPS improved from 70 at the 1st SRS to 82 at the 2nd; the first follow-up mean KPS was 87 (P? Conclusions Long-term follow-up showed that two-session Gamma Knife SRS achieved durable tumor control rates as well as acceptable treatment-related morbidity. This treatment method may potentially merit being offered to patients with large BM who are in poor condition or are otherwise ineligible for standard care.
机译:背景技术尽管目前在多模式疗法方面已有进展,但是大脑转移瘤(BM)仍然是癌症患者发病和死亡的重要原因。本研究的目的是评估2期伽玛刀立体定向放射外科手术(SRS)对大BM患者的疗效和局限性。方法这是一项前瞻性,开放标签和单组研究,分析了连续58例接受2疗程SRS的大BM(≥10?mL)患者。中位年龄为66岁,中位Karnofsky行为状态(KPS)得分为70。SRS是51个大肿瘤的初始治疗(84%),在先前治疗失败的10个肿瘤(16%)后被用作挽救。分级方案为20-30?Gy,分为2个分级,每个分级之间间隔3-4周。分析了总生存期(OS)和神经系统死亡(ND),局部肿瘤控制和KPS。结果中位随访时间为9.0个月。一年和两年的OS率分别为47%和20%。中位操作系统时间为11.8个月(95%CI:5.5-15.6)。死亡原因为5例颅内局部进展,3例脑膜癌变和39例原发灶进展。一年和两年无ND生存率分别为91%和84%。在61个大型BM中,有52个(85%)具有足够的放射学随访数据,其中6个月和12个月的局部肿瘤控制率分别为85%和64%。平均KPS从第一个SRS的70提高到了第二个SRS的82;首次随访平均KPS为87(P?结论)长期随访显示,两疗程伽马刀SRS达到了持久的肿瘤控制率以及可接受的治疗相关发病率。这种治疗方法可能值得推荐。身体状况较差或不符合标准护理条件的大BM患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号